Business Context and Reporting Period
Company: NeOnc Technologies Holdings, Inc. (NTHI)
Filing Type: Form 8-K (Current Report)
Date of Report: June 23, 2026
Reporting Period: Single event date (June 23, 2026)
Business Overview: The Company is an emerging growth company focused on developing non-invasive nose-to-brain delivery systems. Its lead candidate, NEO100, is an intranasally administered formulation of purified perillyl alcohol.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a regulatory milestone and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Regulatory Milestone: On June 23, 2026, the Department of Health – Abu Dhabi (DOH) granted Investigational New Drug (IND) status for NEO100. This approval permits the Company to proceed with clinical trials for its lead candidate in the Abu Dhabi jurisdiction.
Guidance, Outlook, and Risks
Management Commentary: The filing highlights the strategic importance of the IND status for NEO100, validating the Company's non-invasive delivery platform.
Outlook: The grant of IND status enables the next phase of clinical development for NEO100.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard regulatory process implied by the IND application. The press release furnished as Exhibit 99.1 is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific scope and limitations of the IND status granted by the Department of Health – Abu Dhabi.
- Review the full text of the press release (Exhibit 99.1) for details on the planned clinical trial design and timeline.
- Confirm the Company's current cash runway and funding status, as this filing does not disclose financial liquidity.
- Monitor subsequent filings for updates on the initiation of clinical trials following this regulatory approval.